flow trial semaglutide kidney 2024 clinical (funded by Novo Nordisk): showed 24% reduction in the risk of disease-related events in people with type 2 diabetes and chronic kidney disease compared to placebo. Investigators Today's #JACCJournals featured trial in
Description
Although it is not recommended for long-term use
If lower doses were effective, we would have studied them
Theyre also associated with better cardiovascular health when they replace saturated and trans fats
Over time, this can create gaps in essential nutrients like vitamin B12, magnesium, calcium, and vitamin Dall of which play critical roles in maintaining energy, bone health, muscle function, and immune health
Colon disorders such as colon cancer screening / polyp removal, constipation / diarrhea, colitis, IBS, and rectal bleeding
Thanks for the input, everyone
